Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 2Phase NA 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Other hematologic neoplasm 2Plasma cell 1Lymphoid 1Gynecologic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Leukemia, Myeloid, Acute 481Leukemia 287Precursor Cell Lymphoblastic Leukemia-Lymphoma 249Leukemia, Lymphocytic, Chronic, B-Cell 235Myelodysplastic Syndromes 200Lymphoma 148Lymphoma, Non-Hodgkin 143Hematologic Neoplasms 139Recurrence 109Lymphoma, Mantle-Cell 102Lymphoma, Follicular 100Lymphoma, Large B-Cell, Diffuse 96Multiple Myeloma 82Leukemia, Myelogenous, Chronic, BCR-ABL Positive 81Leukemia, Myelomonocytic, Chronic 77Lymphoma, B-Cell, Marginal Zone 75Burkitt Lymphoma 72Hodgkin Disease 69Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 52Lymphoma, B-Cell 50Neoplasms 47Waldenstrom Macroglobulinemia 46Myeloproliferative Disorders 44Blast Crisis 41Lymphoma, Large-Cell, Immunoblastic 38Leukemia, Myeloid, Chronic-Phase 35Leukemia, B-Cell 34Leukemia, Myeloid, Accelerated Phase 33Congenital Abnormalities 32Leukemia, Biphenotypic, Acute 31

Interventions

fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Disease Progression × Other hematologic neoplasm × Clear all
NCT07109323 2025-08-07

Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM

Institute of Hematology & Blood Diseases Hospital, China

Phase 1/2 Recruiting
50 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Disease Progression

NCT04029038 2023-08-21

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡